-
Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.
-
In this downloadable slideset, William Tap, MD, reviews practice-changing clinical data and emerging treatment options for the management of patients with advanced soft tissue sarcomas.
-
In this CME-certified module with downloadable slides, William Tap, MD, reviews practice-changing clinical data and emerging treatment options for the management of patients with advanced soft tissue sarcomas.
-
R. Lor Randall, MD, FACS, and Richard Riedel, MD, discuss key findings in osteosarcomas, soft-tissue sarcomas, and desmoid tumors from the 2011 Combined Meeting of the Connective Tissue Oncology Society and the Musculoskeletal Tumor Society.
-
A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.
|
Latest Content
-
A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.
Date Posted: 6/5/2017
-
In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.
Date Posted: 6/5/2017
-
Richard Finn, MD; Gary K. Schwartz, MD; and Geoffrey Shapiro, MD, PhD, discuss the supporting rationale and emerging role of selective CDK4/6 inhibitors in multiple types of cancer.
Faculty: Richard Finn MD, Gary K. Schwartz MD, Geoffrey Shapiro MD, PhD
Released: 4/14/2017
-
In this downloadable slideset, Richard Finn, MD, Gary K. Schwartz, MD, and Geoffrey Shapiro, MD, PhD provide insight on the rationale for targeting cyclin dependent kinases 4 and 6 in cancer and highlight emerging clinical data with selective CDK4/6 inhibitors in multiple cancers.
Date Posted: 4/14/2017
-
In this text module and accompanying downloadable slideset, experts review the most clinically relevant study results presented at the 2016 ESMO annual meeting across multiple different malignancies including advanced NSCLC, melanoma, breast cancer, ovarian cancer, and glioblastoma.
Faculty: Margaret Callahan MD, PhD, Shirish Gadgeel MD, Ryan T. Merrell MD, Bradley J. Monk MD, FACS, FACOG, Joyce O'Shaughnessy MD
Released: 1/4/2017
-
In this downloadable slideset, William Tap, MD, reviews practice-changing clinical data and emerging treatment options for the management of patients with advanced soft tissue sarcomas.
Date Posted: 4/11/2016
-
In this CME-certified module with downloadable slides, William Tap, MD, reviews practice-changing clinical data and emerging treatment options for the management of patients with advanced soft tissue sarcomas.
Faculty: William Tap MD
Released: 4/11/2016
-
Gain expert perspective from Margaret von Mehren, MD, on the optimal use of targeted agents to improve outcomes in patients with gastrointestinal stromal tumors.
Date Posted: 10/12/2012
-
Margaret von Mehren, MD, reviews the optimal use of imatinib and newer targeted agents to improve outcomes in patients with GIST.
Faculty: Margaret von Mehren MD
Released: 10/12/2012
-
R. Lor Randall, MD, FACS, and Richard Riedel, MD, discuss key findings in osteosarcomas, soft-tissue sarcomas, and desmoid tumors from the 2011 Combined Meeting of the Connective Tissue Oncology Society and the Musculoskeletal Tumor Society.
Faculty: R. Lor Randall MD, FACS, Richard F. Riedel MD
Released: 1/5/2012
|
|
|